| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Halozyme Therapeutics Inc (NASDAQ: HALO)
HALO Technical Analysis
4
| As on 9th Jun 2023 HALO SHARE Price closed @ 33.96 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 42.09 & Sell for SHORT-TERM with Stoploss of 35.77 we also expect STOCK to react on Following IMPORTANT LEVELS. |
HALOSHARE Price
| Open | 34.16 | Change | Price | % |
| High | 34.46 | 1 Day | -0.20 | -0.59 |
| Low | 33.77 | 1 Week | 1.53 | 4.72 |
| Close | 33.96 | 1 Month | 1.72 | 5.33 |
| Volume | 592900 | 1 Year | -5.22 | -13.32 |
| 52 Week High 59.44 | 52 Week Low 30.28 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| HALO Daily Charts |
HALO Intraday Charts |
Whats New @ Bazaartrend |
HALO Free Analysis |
|
|
HALO Important Levels Intraday
| RESISTANCE | 35.29 |
| RESISTANCE | 34.86 |
| RESISTANCE | 34.60 |
| RESISTANCE | 34.34 |
| SUPPORT | 33.58 |
| SUPPORT | 33.32 |
| SUPPORT | 33.06 |
| SUPPORT | 32.63 |
HALO Forecast April 2024
| 4th UP Forecast | 48.53 |
| 3rd UP Forecast | 43.86 |
| 2nd UP Forecast | 40.97 |
| 1st UP Forecast | 38.08 |
| 1st DOWN Forecast | 29.84 |
| 2nd DOWN Forecast | 26.95 |
| 3rd DOWN Forecast | 24.06 |
| 4th DOWN Forecast | 19.39 |
HALO Weekly Forecast
| 4th UP Forecast | 39.09 |
| 3rd UP Forecast | 37.44 |
| 2nd UP Forecast | 36.43 |
| 1st UP Forecast | 35.41 |
| 1st DOWN Forecast | 32.51 |
| 2nd DOWN Forecast | 31.49 |
| 3rd DOWN Forecast | 30.48 |
| 4th DOWN Forecast | 28.83 |
HALO Forecast2024
| 4th UP Forecast | 91.02 |
| 3rd UP Forecast | 72.72 |
| 2nd UP Forecast | 61.41 |
| 1st UP Forecast | 50.1 |
| 1st DOWN Forecast | 17.82 |
| 2nd DOWN Forecast | 6.51 |
| 3rd DOWN Forecast | -4.8 |
| 4th DOWN Forecast | -23.1 |
Halozyme Therapeutics Inc ( NASDAQ USA Symbol : HALO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
HALO Business Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Address: 11388 Sorrento Valley Road, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service